Choosing when to stop immunotherapy is an extremely difficult decision process – in this blog piece melanoma survivor T.J. Sharpe shares his thoughts on the recent KEYNOTE-006 data.
Genetic test could identify prostate cancer patients who are most likely to benefit from immunotherapy
A genetic test could aid the identification of men with prostate cancer who are most likely to benefit from immunotherapy.
Today’s plenary session has revealed some of the biggest stories from ASCO; find out further details of CARMENA, KEYNOTE-042 and TAILORx plus much more by clicking the link below.
Results of the KEYNOTE-042 study have demonstrated pembrolizumab to be more effective in most patients with the most common form of lung cancer, in comparison to the current standard-of-care, namely, chemotherapy.
Keytruda® has significantly improved overall survival and progression-free survival as a first-line treatment for squamous non-small cell lung cancer in the Phase III KEYNOTE-407 trial.
In this patient perspective find out T.J.’s viewpoint on the potentially practice-changing lung cancer findings presented at the AACR 2018.
Details of the KEYNOTE-189 study have been announced by Merck (known as MSD outside the United States and Canada).
Keep checking back throughout the conference, we will be updating this article with the biggest news headlines from the American Association for Cancer Research (AACR) Annual Meeting 2018 (April 14–18, IL, USA).
Positive late-stage data has been announced from the KEYNOTE-054 trial, investigating KEYTRUDA® (pembrolizumab) in high-risk stage III melanoma patients.
Discover details of the KEYNOTE-045, which recently resulted in the recommendation for the use of pembrolizumab within the cancer drugs fund as an option for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.